Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,606 recruiting studies in this area right now.
By phase
- Not applicable4,685
- Phase 21,189
- Phase 1568
- Phase 3457
- Phase 1/Phase 2368
- Phase 4229
- Phase 2/Phase 3110
Top conditions
- Colorectal Cancer479
- Pancreatic Cancer287
- Gastric Cancer283
- Hepatocellular Carcinoma256
- Esophageal Cancer189
- Rectal Cancer168
- Breast Cancer146
- Crohn Disease134
- Ulcerative Colitis129
- Colon Cancer114
- Hepatocellular Carcinoma (HCC)112
- Liver Cancer99
- Lung Cancer95
- Inflammatory Bowel Diseases94
- Pancreas Cancer90
- Ovarian Cancer89
- Esophageal Squamous Cell Carcinoma86
- Cystic Fibrosis77
Leading sponsors
- Fudan University100
- Sun Yat-sen University85
- Mayo Clinic75
- Second Affiliated Hospital, Zhejiang University, School of Medicine56
- Chinese University of Hong Kong55
- M.D. Anderson Cancer Center55
- Assistance Publique - Hôpitaux de Paris53
- Sixth Affiliated Hospital, Sun Yat-sen University51
- National Cancer Institute (NCI)50
- National Taiwan University Hospital45
Where studies are running
- California442
- Arizona190
- Texas140
- Alabama129
- Florida127
- New York120
- Massachusetts119
- Maryland88
- Ohio80
- Illinois69
Recruiting studies7,606 total
- NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT06691061Recruiting
Comparing advanced treatments for ulcerative colitis after anti-TNF therapy
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Mialn, ItalyAges 18 years+ - NCT06690476RecruitingEarly Phase 1
Study of IPM514 for esophageal cancer
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
BeijingAges 18 years+ - NCT05370144Recruiting
Pre-surgery chemotherapy and radiation for esophagus cancer
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
Calgary, AlbertaAges 18–80 - NCT06313190RecruitingPhase 2
SBRT plus immunotherapy for small liver cancer
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT05933876Recruiting
Radiation study for limited spread cancer
This trial looks at whether giving radiation treatment to tumors in people with a limited number of metastases can help control the cancer. It is for adults with certain cancer types that have spread to specific organs, and who can manage daily activities with little or no help.
Albacete, AlbaceteAges 18 years+ - NCT04880356Recruiting
Study of very rare inherited brain diseases over time
This study follows adults over time who have a very rare inherited brain disease, or whose illness seems like it may run in families. The goal is to better understand these conditions and how they progress.
Milan, MilanoAges 18 years+ - NCT06693375RecruitingPhase 2
Testing a new imaging agent for rectal cancer lymph nodes
This trial tests a new nanoparticle-based imaging agent to better see lymph nodes near the rectum. It first checks healthy volunteers for safety, then studies people with rectal cancer to see if it can help guide surgery.
UppsalaAges 18–99 - NCT07629817RecruitingPhase 3
Surgery vs. Chemoradiation for Esophageal Cancer
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
Zhengzhou, HenanAges 18–75 - NCT04588077RecruitingPhase 4
Two-dose vs three-dose hepatitis B vaccine for cirrhosis
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Baltimore, MarylandAges 18 years+ - NCT07635784Recruiting
Hemorrhoid Treatment Registry: Tracking Embolization Safety
This registry collects information about a minimally invasive procedure called hemorrhoidal artery embolization (HAE), which blocks blood vessels feeding internal hemorrhoids. It's for adults with persistent bleeding hemorrhoids that haven't improved with standard treatments like creams or medications.
Libertyville, IllinoisAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07632573RecruitingPhase 1
Safety Study of BDHK-2009 Tablets in Healthy Adults
This is an early-stage safety study testing a new experimental tablet called BDHK-2009 in healthy volunteers with no major illnesses. Researchers want to make sure the drug is safe and well-tolerated before testing it in people with medical conditions.
Hangzhou, ZhejiangAges 18–55 - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT06693622Recruiting
Patient preferences for Barrett's esophagus screening tests
This study asks people at risk for Barrett's esophagus (a condition that can lead to esophageal cancer) to share which screening test they prefer. Your answers help researchers understand what matters most to patients when choosing a screening method.
Aurora, ColoradoAges 18–89 - NCT05618626Recruiting
Lifestyle program to prevent fatty liver and heart disease
This trial tests whether a structured lifestyle program—focused on healthy living and resistance exercise—can help prevent fatty liver disease and heart-related problems. It may be helpful if you have early or mild fatty liver changes or risk factors, even if you also have gallstones.
Molina, Maule RegionAges 45–60 - NCT05436054RecruitingPhase 4
Plenvu vs Picoprep bowel prep for colonoscopy
This study compares two bowel-cleansing products (Plenvu and Picoprep) to see which works better and is easier to tolerate before a colonoscopy. It may help patients by improving the chance of a clear exam and reducing unpleasant side effects.
Aalborg, North JutlandAges 18 years+ - NCT07629986Recruiting
How antibiotics work in cystic fibrosis patients on ETI therapy
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
RoscoffAges 12 years+ - NCT07634562RecruitingPhase 1/Phase 2
Reducing immune-suppressing drugs after liver transplant
This study tests a new way to lower the amount of immune-suppressing medicine needed after a liver transplant. It uses special treatments before or during the transplant to help your body accept the new liver with fewer drugs, which may reduce side effects.
Stanford, CaliforniaAges 18–55 - NCT07636824RecruitingPhase 2
Chemotherapy plus radiation after bile duct cancer surgery
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
BeijingAges 18–80
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,606 recruiting gastroenterology studies from the U.S. registry right now, out of 11,952 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.